GenMark Diagnostics announced that it has received clearance from the FDA for its eSensor Respiratory Virus Panel (RVP) for use on its XT-8 system, intended to simultaneously detect and differentiate 14 clinically relevant viruses from patients with influenza-like illness.

The eSensor RVP test delivers co-infection detection, distinguishing Rhinovirus from Enteroviruses and identifying clinically relevant Adenoviruses. The eSensor RVP test enables laboratories to report patient results with rapid processing and minimal hands-on time.

GenMark currently markets four tests that are FDA cleared: Respiratory Viral Panel, Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, and Thrombophilia Risk Test.

For more information call (800) 373-6767 or visit www.genmarkdx.com.